课题基金 / 基金详情

Elucidation of aggregation mechanism of Alzheimer's β-peptides and development of their aggregation inhibitors

Elucidation of aggregation mechanism of Alzheimer's β-peptides and development of their aggregation inhibitors
阿尔茨海默病β肽聚集机制的阐明及其聚集抑制剂的开发
批准号:
13460048
负责人:
IRIE Kazuhiro
金额:
$9.66万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2003

项目摘要

项目成果

IRIE Kazuhiro的其他基金

相似基金

相关文献

中文摘要
翻译
阿尔茨海默病的神经病理学特征是淀粉样蛋白在辫状实质和皮质血管中的进行性沉积。这种沉积物主要由40和42聚体的β淀粉样肽(Aβ40、Aβ42)组成,具有神经毒性和聚集能力。家族性阿尔茨海默病中的脑淀粉样血管病(CAA)与这些Aβ肽编码区内的错义突变有关。为了阐明Aβ肽的聚集机制,我们合成了CAA中发现的Aβ40和Aβ42的所有变体,并以高纯度的形式在PC 12细胞中检测了它们的神经毒性和聚集能力,所有Aβ40 22和23位突变体都显示出比野生型Aβ40更强的神经毒性。Aβ42 22和23位突变体的神经毒性也有类似的趋势,其神经毒性是相应Aβ40突变体的50 ~ 200倍,表明这些Aβ42突变体主要参与CAA的发病。特别是,E 关于我们 22 Q-A β42(荷兰)和E22 K-A β42(意大利)广泛聚集,支持荷兰和意大利患者被诊断为遗传性脑出血伴淀粉样变性的临床证据。相比之下,A21 G(佛兰芒)突变除了Aβ突变体的理化性质外,还需要其他解释。FI-IR光谱表明聚集增加了Aβ肽的β折叠含量。然而,转角也是聚集的关键二级结构,因为22和23位的残基优选形成两个残基的β-转角显著增强聚集能力。只有E22 P-A β42广泛聚集,神经毒性比野生型Aβ42强,表明15 - 21和24 - 32位残基参与分子间β折叠的形成,22和23位转角的形成在Aβ肽的聚集和神经毒性中起关键作用。这些发现为设计新的Aβ肽聚集抑制剂奠定了基础。少
英文摘要
Alzheimer's disease is neuropathologically characterized by the progressive deposition of amyloid in the braid parenchyma and cortical blood vessels. This deposition mainly consists of 40-and 42-mer β-amyloid peptides (Aβ40, Aβ42) which show neurotoxicity and aggregative ability. Cerebral amyloid angiopathy (CAA) in familial Alzheimer's disease is related to missense mutations inside the coding region of these Aβpeptides. In order to clarify the aggregation mechanism of Aβpeptides, all of the variants of Aβ40 and Aβ42 found in CAA were synthesized in a highly pure form and examined for neurotoxicity in PC12 cells and aggregative ability.All of the Aβ40 mutants at positions 22 and 23 showed stronger neurotoxicity than wild-type Aβ40. Similar tendency was observed for Aβ42 mutants at positions 22 and 23 whose neurotoxicity was 50〜200 times stronger than that of the corresponding Aβ40 mutants, indicating that these Aβ42 mutants are mainly involved in the pathogenesis of CAA. Especially, E … More 22Q-Aβ42 (Dutch) and E22K-Aβ42 (Italian) aggregated extensively, supporting the clinical evidence that Dutch and Italian patients are diagnosed as hereditary cerebral hemorrhage with amyloidosis. In contrast, A21 G (Flemish) mutation needs alternative explanation with the exception of physicochemical properties of Aβmutants. The FI-IR spectra suggested that aggregation increases theβ-sheet contents of the Aβpeptides. However, turn was also a critical secondary structure for aggregation since residues at positions 22 and 23 that preferably form two-residue β-turn significantly enhanced the aggregative ability.To identify amino acid residues that are important for the β-sheet formation, a series of proline-substituted mutants of Aβ42 was synthesized and their aggregative ability and neurotoxicity were investigated. Only E22P-Aβ42 extensively aggregated with stronger neurotoxicity than wild-type Aβ42, suggesting that the residues at positions 15〜21 and 24〜32 are involved in the intermolecular β-sheet formation, and that turn formation at positions 22 and 23 plays a crucial role in the aggregation and neurotoxicity of Aβpeptides. These findings become a basis for designing new aggregation inhibitors of Aβpeptides. Less
期刊论文(18)
专著(0)
科研奖励(0)
会议论文
Kazuma Murakami: "Neurotoxicity and physicochemical properties of Aβ mutant peptides from cerebral amyloid angiopathy"The Journal of Biological Chemistry. 278・46. 46179-46187 (2003)
Kazuma Murakami:“脑淀粉样血管病的 Aβ 突变肽的神经毒性和理化特性”生物化学杂志 278・46(2003)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kazuma Murakami, Kazuhiro Irie et al.: "Synthesis, aggregation, neurotoxicity, and secondary structure of various Aβ1-42 mutants of familial Alzheimer's disease at positions 21-23"Biochem.Biophys.Res.Commun.. 294 (1). 5-10 (2002)
Kazuma Murakami、Kazuhiro Irie 等人:“家族性阿尔茨海默氏病 21-23 位的各种 Aβ1-42 突变体的合成、聚集、神经毒性和二级结构”Biochem.Biophys.Res.Commun. 294 (1)。 -10 (2002)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kazuma Murakami: "Synthesis, aggregation, neurotoxicity, and secondary structure of various β1-42 mutants of familial Alzheimer's disease at positions 21-23"Biochemical and Biophysical Research Communications. 294・1. 5-10 (2002)
Kazuma Murakami:“家族性阿尔茨海默病的各种β1-42突变体在位置21-23的合成、聚集、神经毒性和二级结构”《生物化学和生物物理研究通讯》294·1(2002)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kazuma Murakami: "Synthesis, aggregation, neurotoxicity, and secondary structure of various Aβ1-42 mutants of familial Alzheimer's disease at positions 21-23"Biochemical and Biophysical Research Communications. 294・1. 5-10 (2002)
Kazuma Murakami:“家族性阿尔茨海默氏病的各种 Aβ1-42 突变体在位置 21-23 的合成、聚集、神经毒性和二级结构”《生物化学和生物物理研究通讯》294·1(2002)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
8
    Search for novel PKC ligands as therapeutic seeds for intractable diseases
    • 批准号:
      23658100
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2011
    • 负责人:
      IRIE Kazuhiro
    • 依托单位:
    Development of medicinal seeds for Alzheimer's disease based on the structural analysis of toxic oligomers of amyloid beta
    • 批准号:
      21248015
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $29.45万
    • 财政年份:
      2009
    • 负责人:
      IRIE Kazuhiro
    • 依托单位:
    Development of antibodies and aggregation inhibitors for amyloid β peptides based on the new aggregation model
    • 批准号:
      18208011
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $24.29万
    • 财政年份:
      2006
    • 负责人:
      IRIE Kazuhiro
    • 依托单位:
    Synthesis and characterization of the regulatory domains of protein kinase C
    • 批准号:
      11660109
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      1999
    • 负责人:
      IRIE Kazuhiro
    • 依托单位:
    国内基金
    海外基金
    FBXO42 经 Ube2m-Rbx1 轴促进 STAT3 介导的巨噬细胞线粒体自噬抗动脉粥样硬化的机制研究
    • 批准号:
      ZCLQN26H0201
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      陈凌燕
    • 依托单位:
    基于CsDof16-CLE42模块的茶树氮高效育种靶点挖掘与机制研究
    • 批准号:
      2026JJ80722
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      费雁泉
    • 依托单位:
    Cdc42通过抑制GSK-3β激酶活性介导YAP/TAZ异常激活在骨关节炎滑膜纤维化中的作用机制研究
    小G蛋白Cdc42激活mTOR信号通路引发线粒体功能障碍:癌痛吗啡耐受机制的新视角
    • 批准号:
      2026JJ81115
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      李晴
    • 依托单位: